Squarepoint’s Arbutus Biopharma ABUS Stock Holding History

Squarepoint’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25,000	Closed	-$87.3K	–	4422
2025 Q1	$87.3K	Sell	25,000 -159,500	-86%	-$532K	﹤0.01%	4256
2024 Q4	$603K	Buy	+184,500	New	+$679K	﹤0.01%	3567

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Squarepoint's ABUS Position: Q1 2026 in Review

Squarepoint sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 28,775 shares — an estimated $138K sold.

Squarepoint first reported a position in ABUS in Q4 2016 and held it in 16 quarters. The position peaked at $586K in Q2 2020. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Squarepoint reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
Squarepoint sold 28,775 Arbutus Biopharma shares in Q1 2026, an estimated $138K.
Squarepoint first reported a position in Arbutus Biopharma in Q4 2016 and held it in 16 quarters.
Squarepoint's Arbutus Biopharma position peaked at $586K in Q2 2020.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.